Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

ONTX was devalued by Zacks.com  from a “buy” score to a “hold” score in a research note released to capitalists on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It focuses on discovering as well as creating small molecule medication candidates to deal with cancer cells. The Business‘s products under various stages of growth include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous various other equities research analysts additionally recently discussed the business. Noble Financial editioned a “acquire” score and also issued a $11.00 price goal on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 as well as established a “get” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. The business has a 50 day moving typical cost of $2.90 as well as a two-hundred day moving average price of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) earnings per share for the quarter, covering experts’ agreement estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% and also a negative web margin of 8,294.27%. The firm had profits of $0.06 million throughout the quarter, contrasted to the agreement estimate of $0.06 million. During the same quarter in the prior year, the firm posted ($ 0.45) EPS. En masse, research analysts forecast that Onconova Therapeutics will post -1.18 EPS for the existing year.

A number of hedge funds have actually lately bought and sold shares of ONTX. GSA Capital Partners LLP got a new position in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Resources Management LP purchased a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC bought a new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC acquired a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $493,000. Lastly, Dimensional Fund Advisors LP acquired a new placement in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and also other institutional financiers have 13.36% of the business’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which engages in the identification and growth of oncology therapeutics. It concentrates on finding as well as establishing tiny molecule drug prospects to deal with cancer cells. The business was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a cost-free copy of the Zacks research record on Onconova Therapeutics (ONTX).

To find out more about research offerings from Zacks Investment Research, browse through Zacks.com.

This immediate information alert was created by narrative science modern technology as well as monetary data from Market in order to provide viewers with the fastest as well as most precise reporting. This tale was reviewed by Market’s editorial group prior to magazine. 



Prior to you think about Onconova Therapeutics, you’ll intend to hear this.

Market tracks Wall Street’s premier as well as finest doing research analysts as well as the stocks they advise to their clients each day. Market has determined the five stocks that top analysts are silently murmuring to their customers to purchase currently prior to the broader market catches on … and also Onconova Therapeutics wasn’t on the list.

While Onconova Therapeutics currently has a “Buy” ranking among experts, premier experts think these 5 stocks are much better acquires.